Phosphodiesterase 5 Inhibitor Global Market Report 2025

The phosphodiesterase 5 inhibitor market size is expected to see strong growth in the next few years. It will grow to $6.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. In the forecast period, growth is expected to be driven by a rising demand for oral, non-invasive therapeutics, greater adoption of telemedicine for sexual health treatment, an increasing focus on personalized medicine, and a growing emphasis on male fertility treatments. Key trends during this period include the development of combination therapies, integration with combination pill regimens, innovation in targeted therapies, the emergence of non-pharmaceutical alternatives, and the integration of artificial intelligence in PDE5-targeted drug discovery.

The growing prevalence of erectile dysfunction is expected to drive the growth of the phosphodiesterase 5 inhibitor market. Erectile dysfunction (ED) is defined by the consistent inability to achieve or maintain an erection adequate for satisfactory sexual performance. The rising prevalence of ED is largely attributed to hormonal imbalances, particularly low testosterone levels, which affect sexual function and performance. Phosphodiesterase 5 inhibitors help treat erectile dysfunction by enhancing blood flow to the penis, allowing men to achieve and sustain an erection in response to sexual stimulation. For example, in December 2024, LloydsPharmacy Online Doctor, a UK-based pharmacy, reported that in 2023, the NHS issued nearly 3.5 million prescriptions for Viagra, leading to the distribution of about 25.5 million pills between September 2023 and August 2024. This growing prevalence of erectile dysfunction is fueling the expansion of the phosphodiesterase 5 inhibitor market.

The rise in research and clinical trials is also expected to boost the growth of the phosphodiesterase 5 inhibitor market. Clinical trials are research studies involving human participants designed to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The increase in clinical trials is primarily driven by the demand for new treatments to address evolving healthcare needs and enhance patient outcomes. Phosphodiesterase 5 inhibitors support the clinical trial process by improving the evaluation of therapeutic efficacy for conditions like erectile dysfunction and pulmonary hypertension, thus aiding the development of more targeted treatments. For instance, a report from the Association of the British Pharmaceutical Industry (ABPI) in November 2023 noted that the total number of industry clinical trials initiated annually in the UK rose by 4.3%, from 394 trials in 2021 to 411 in 2022. As a result, the growth in research and clinical trials is expected to propel the phosphodiesterase 5 inhibitor market forward.

Major companies in the phosphodiesterase 5 inhibitor market are focusing on developing innovative products, such as generic versions of Stendra. These generics contain the same active ingredient, avanafil, and help treat erectile dysfunction by inhibiting the PDE5 enzyme, which enhances blood flow to the penis. In October 2024, Camber Pharmaceuticals, Inc., a US-based pharmaceutical company, launched Avanafil tablets in 50 mg, 100 mg, and 200 mg strengths, each available in 30-count bottles. Avanafil works by improving blood flow to the penis during sexual stimulation, with effects typically felt within 15 minutes and lasting for more than six hours.

Major players in the phosphodiesterase 5 inhibitor market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, GlaxoSmithKline plc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Apotex Inc, Aurobindo Pharma Ltd, Dr. Reddy’s Laboratories Ltd., Cipla Ltd, Lupin Limited, Torrent Pharmaceuticals Ltd., Vectura Group, Vivus Inc, Seoul Pharma, Auxilium Pharmaceuticals, Metuchen Pharma.

North America was the largest region in the phosphodiesterase 5 inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phosphodiesterase 5 inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phosphodiesterase 5 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phosphodiesterase 5 inhibitor market consists of sales of products including sildenafil, tadalafil, vardenafil, avanafil, and lodenafil. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A phosphodiesterase 5 (PDE5) inhibitor is a type of drug that blocks the enzyme PDE5, which normally breaks down cyclic guanosine monophosphate (cGMP). This molecule plays a key role in relaxing smooth muscle tissue and increasing blood flow. PDE5 inhibitors are commonly used to treat erectile dysfunction and pulmonary arterial hypertension by improving blood flow in targeted areas.

The main types of phosphodiesterase 5 inhibitors include sildenafil, tadalafil, vardenafil, avanafil, and others. Sildenafil is used to treat erectile dysfunction and pulmonary arterial hypertension by relaxing blood vessels and boosting blood flow to specific areas. These medications come in various forms, such as tablets, injectables, and topical applications. They are used to treat conditions like erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia, and other related disorders. These drugs are distributed through retail pharmacies, online pharmacies, and hospital pharmacies, and are used in hospitals, specialty clinics, and home care settings.

The phosphodiesterase 5 inhibitor market research report is one of a series of new reports that provides phosphodiesterase 5 inhibitor market statistics, including the phosphodiesterase 5 inhibitor industry's global market size, regional shares, competitors with the phosphodiesterase 5 inhibitor market share, detailed phosphodiesterase 5 inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the phosphodiesterase 5 inhibitor market. This phosphodiesterase 5 inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The phosphodiesterase 5 inhibitor market size has grown strongly in recent years. It will grow from $4.43 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of erectile dysfunction, heightened awareness about sexual health, a growing geriatric population, a rising preference for non-invasive treatment options, and an increase in lifestyle-related diseases.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.